Tasly Pharmaceuticals, Inc., a global leader in pharmaceuticals, biologics, and nutraceuticals, held a ribbon-cutting ceremony on September 3, 2014, at Tasly’s corporate offices in Rockville, MD.
The ceremony marked the official launch of Tasly’s Rockville location as the North American headquarters of Tasly Holding Group, a twenty year old global technology company established in China.
More than 100 distinguished guests and dignitaries were in attendance, including the Chairman and the President of Tasly Holding Group, China’s Embassy Counselor, Maryland state officials, Maryland biotechnology and pharmaceutical executives, and high-level regional media representatives, among others.
Dr. Xijun Yan, Tasly Chairman, noted that the launch of Tasly Pharmaceuticals is “one of the most important business strategies” that Tasly is pursuing on its path to global commercialization. He further added that the parent company will “fully support” Tasly Pharmaceuticals, Inc.’s business objectives and initiatives in the United States, as the company’s products will “help fulfill the unmet needs of the U.S. medical community.” Finally, he emphasized that Tasly’s portfolio of biologics, pharmaceuticals, and health management services generated $4 billion in revenues in 2013.
Mr. Dominick Murray, Secretary of Maryland’s Department of Business and Economic Development, noted that “China’s herbal medicine has been known for centuries for its unique and natural healing properties.” The State of Maryland, home to more than 500 biotech companies, is therefore “excited to welcome Tasly Pharmaceuticals, Inc.” to its flourishing business community.
Tasly, whose pharmaceutical products have been approved by national health regulatory authorities in 34 countries worldwide, is currently undergoing the U.S. FDA Phase III Clinical Trials for its cardio-tonic pill, intended for treatment of stable angina pectoris. The revolutionary pill is expected to be the first-ever multi herb-based and chemical-free pharmaceutical product approved by the FDA.
Tasly plans to inaugurate its multi-faceted product portfolio with Deepure, Tasly’s line of nutraceuticals. They encompass three condition-specific, whole-food and herb-based formulas, including PRO-Heart PLUS, ImmunoPower PLUS, and Re-Memory PLUS. All three formulas are gluten-free and made without chemicals, preservatives, artificial colors, flavors, sweeteners, or gelatin. Deepure will be available at leading food and drug retailer outlets nationwide, beginning this fall.
For more information about Tasly Pharmaceuticals, Inc. and Deepure, please visit www.taslyus.com.